Resource impact template

Following publication of NICE technology appraisal guidance on apremilast (TA419) and ixekizumab (TA442) for treating moderate to severe psoriasis, the resource impact template for secukinumab (TA350) has been updated to include apremilast and ixekizumab as further treatment options.

The template includes all current NICE recommended biological treatments for plaque psoriasis and the non- biological treatment apremilast.

This page was last updated: 20 June 2017